To unravel whether bTMB could identify patients benefiting from ICB therapy, another independent cohort of 50 patients with advanced NSCLC treated with anti–PD-1 and anti–PD-L1 agents (cohort 2) (eFigure 2B and eTable 5 in the Supplement) was used for analysis. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.